Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Pharming Group Announces Development Plans For Leniolisib For Additional Primary Immunodeficiencies (Pids) menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
The multinational Phase III study is evaluating a new pediatric granulated formulation of leniolisib in children aged 1 to 6 years with APDS, a rare primary immunodeficiency Leiden, The Netherlands, November 21,
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. announces that it has received a Day 180 Second List of Outstanding Issues from the European Medicines Agency’s Committee for.
Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quart